CCL4/CCR5 regulates chondrocyte biology and OA progression

Area of Science:

• Biomedical Research
• Molecular Biology
• Pathology

Background:

• Osteoarthritis (OA) is a degenerative musculoskeletal disorder.
• Key features include chondrocyte apoptosis and extracellular matrix degradation.
• The role of CCL4/CCR5 in OA pathogenesis requires elucidation.

Purpose of the Study:

• Investigate the function of CCL4/CCR5 in OA progression.
• Determine the impact of CCL4/CCR5 on chondrocyte apoptosis and reactive oxygen species (ROS) levels.
• Explore the underlying molecular mechanisms.

Main Methods:

• Bioinformatics analysis identified CCL4 as a target gene.
• Primary chondrocytes were treated with CCL4 and assessed for apoptosis and ROS.
• Western blot and immunofluorescence analyzed extracellular matrix regulation.
• CCR5 inhibitor (maraviroc) was used to probe the CCL4/CCR5 pathway.

Main Results:

• CCL4 was upregulated in OA patients and associated with increased chondrocyte apoptosis and ROS.
• CCL4/CCR5 signaling activated the NF-κB pathway via P65 phosphorylation.
• Maraviroc treatment reduced apoptosis, ROS, and extracellular matrix degradation in vitro.

Conclusions:

• The CCL4/CCR5 pathway is a critical regulator of chondrocyte apoptosis and ROS in OA.
• Targeting the CCL4/CCR5 pathway presents a potential therapeutic strategy for OA.
• Further research into this pathway could yield novel OA treatments.